Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammad Shahzad

Internal Medicine Danville, KY Medical Doctor

NPI 1609830462 CMS profile 117484

105 Ponder Ct, Suite 104, Danville, KY 40422

Open in the dashboard

General payments

$9,718

628 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammad Shahzad of Danville, KY is reported in the CMS Open Payments database as having received $9,718 across 628 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,153 66
2024 General $1,756 90
2023 General $2,051 128
2022 General $1,348 85
2021 General $824 59
2020 General $1,110 80
2019 General $1,475 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammad Shahzad
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mohammad Shahzad were reported at $1,153. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mohammad Shahzad Internal Medicine median Middle half National median
2019 $1,475 $159 $48–$570 $163
2020 $1,110 $119 $33–$402 $114
2021 $824 $135 $37–$521 $132
2022 $1,348 $141 $42–$496 $149
2023 $2,051 $149 $45–$519 $160
2024 $1,756 $154 $47–$537 $164
2025 $1,153 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,425 121 payments
  2. GlaxoSmithKline, LLC. $945 60 payments
  3. Lilly USA, LLC $859 56 payments
  4. AbbVie, Inc. $809 58 payments
  5. AstraZeneca Pharmaceuticals LP $708 32 payments
  6. Pfizer Inc. $489 40 payments
  7. Novartis Pharmaceuticals Corporation $463 26 payments
  8. Amgen Inc. $453 29 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $416 21 payments
  10. Merck Sharp & Dohme Corporation $358 22 payments
  11. Other $2,792 163 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,647 622 payments
  2. Education $70 6 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $849 53 payments
  2. Ozempic $648 48 payments
  3. MOUNJARO $570 37 payments
  4. RYBELSUS $544 37 payments
  5. VRAYLAR $408 28 payments
  6. LEQVIO $384 21 payments
  7. Saxenda $299 34 payments
  8. Repatha $282 19 payments
  9. BREZTRI $257 9 payments
  10. COLOGUARD $256 22 payments
  11. Other $8,470 535 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 216 drugs

Part D claims

19,880

Median for Internal Medicine: 777

Drug cost

$1,924,776

Median for Internal Medicine: $73,373

Branded share of claims

21.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 268 $266,019
Ozempic Semaglutide Brand 162 $211,101
Eliquis Apixaban Brand 197 $174,102
Tresiba Flextouch U-200 Insulin Degludec Brand 154 $153,670
Trulicity Dulaglutide Brand 122 $134,862
Mounjaro Tirzepatide Brand 76 $88,936
Januvia Sitagliptin Phosphate Brand 96 $83,321
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 77 $81,408
Linzess Linaclotide Brand 59 $54,877
Repatha Sureclick Evolocumab Brand 53 $54,462

The 10 drugs with the highest cost, of 216 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$4,772

Medicare's payments for the services billed

Medicare patients

234

Average age 74

Services billed

474

147 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 55%
Arthritis 47%
Ischemic heart disease 34%
Atrial fibrillation 28%
Depression 26%
Chronic kidney disease 22%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$182 11 —
LEQVIO
$177 — —
BREZTRI
$131 — —
TRELEGY ELLIPTA
$120 77 —
MOUNJARO
$101 76 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

628 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record